After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Hypercortisolism is tied to multiple cardio-renal-metabolic disorders, making cortisol level screening an important part of ...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...